K2HV converts $2.5M loan principal into 2.85M NMRA shares at $0.8774/share

Neumora Therapeutics, Inc.

K2 HealthVentures converted $2.5M of term-loan principal into 2,849,327 common shares of NMRA at $0.8774/share.
Conversion was exercised under loan agreement dated May 9, 2025, as amended November 4, 2025.
Shares were issued in reliance on Section 4(a)(2) exemption from registration.
Total conversion right under loan agreement remains up to $12.5M; $10M principal remains convertible.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.